MYC and cancer: A combination of CAPE and Docetaxel induces CaP cell deaths and suppresses cancer proliferation and progression by downregulating the expression of anti-apoptotic markers and caspase activation, Bcl-2, AKT-2, c-MYC, and pyruvate kinase M2.